Progressive multifocal leukoencephalopathy in systemic lupus erythematosus managed with pembrolizumab: A case report with literature review

Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy

(2020) Erin S Beck et al.   Current Opinion in Virology

Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study

(2019) Alessio Cortellini et al.   ONCOLOGIST

Progressive multifocal leukoencephalopathy treated with nivolumab

(2019) Ethan Hoang et al.   JOURNAL OF NEUROVIROLOGY

Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy

(2019) Irene Cortese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab

(2019) Sebastian Rauer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab

(2019) Ondine Walter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sustained Response and Rationale of Programmed Cell Death-1-Targeting for Progressive Multifocal Leukoencephalopathy

(2019) Alexandra Audemard-Verger et al.   Open Forum Infectious Diseases

Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency

(2019) Clemens Küpper et al.   Neurology-Neuroimmunology & Neuroinflammation

Ineffective treatment of PML with pembrolizumab

(2019) Marc Pawlitzki et al.   Neurology-Neuroimmunology & Neuroinflammation

Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus

(2019) Misato Jono et al.   INTERNAL MEDICINE

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease

(2018) Noha Abdel-Wahab et al.   ANNALS OF INTERNAL MEDICINE

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

(2018) François-Xavier Danlos et al.   EUROPEAN JOURNAL OF CANCER

Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience

(2018) Michael D. Richter et al.   Arthritis & Rheumatology

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

(2016) A. M. Menzies et al.   ANNALS OF ONCOLOGY

Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review

(2016) C E Henegar et al.   LUPUS

Progressive multifocal leukoencephalopathy: current treatment options and future perspectives

(2015) Dejan Pavlovic et al.   Therapeutic Advances in Neurological Disorders

A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes

(2013) David B. Clifford et al.   JOURNAL OF NEUROVIROLOGY

A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia

(2010) A. Patel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

(2010) Chen S Tan et al.   LANCET NEUROLOGY

Mirtazapine Use in Human Immunodeficiency Virus–Infected Patients With Progressive Multifocal Leukoencephalopathy

(2009) Deanna Cettomai et al.   ARCHIVES OF NEUROLOGY